Radiation Therapy Planning by Multi-parametric PET/MRI Imaging in Patients With Cervical Cancer

Cervical Cancer Clinical Trial

— RaPiCCa  

Official title:

Radiation Therapy Planning by Multi-parametric PET/MRI Imaging in Patients With Cervical Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03655977
• Other study ID #: H-17016438
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 1, 2018
• Est. completion date: September 1, 2021

Study information

• Verified date: August 2018
• Source: Rigshospitalet, Denmark
• Contact: Heidi Ryssel
• Phone: +4528727532
• Email: heidi.ryssel[@]regionh.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main goal of this project is to evaluate the potential and feasibility of hybrid PET/MRI functional imaging to non-invasively measure tumor characteristics for radiation therapy planning (RT) for cervical cancer. It will be assessed how the complementary information of tumor characteristics can contributed to better understanding of tumor delineation. Another endpoint of this study is to evaluate a new PET-tracer (68Ga-NODAGA- E[c(RGDyK)]2) enabling imaging of tumor-angiogenesis.

Description:

The standard treatment for patients with locally advanced cervical cancer includes a combination of external beam radiotherapy (EBRT) and brachytherapy (BT) with concurrent cisplatin-based chemotherapy. During the last decade, the utilization of MRI for planning of EBRT and BT has grown based on the GEC ESTRO recommendations and the cervix is among the first cancer sites where response-adaptive radiotherapy has been successfully implemented in clinical practice. This approach has changed patterns of clinical practice with regard to dose administration, and significant improvements in clinical outcome have been reported. However further development of both BT and EBRT is still demanded to improve tumor delineation and consequently local control.

Recent developments in advanced image guidance for both EBRT and BT have potential to improve local as well as nodal and also systemic control. Multi-parametric PET/MR imaging potentially offers new possibilities for RT planning, whereas a complete replacement of the planning MRI with combined PET/MRI for EBRT and BT, alters target volume delineation due to superior soft tissue contrast provided by MRI and combined with the information of tumor heterogeneity, perfusion characteristics, and hypoxia provided by PET, DW-MRI, and DCE-MRI. However combined use of PET/MRI for treatment planning still remains challenging due to several aspects. Therefore, investigators intend to encounter the technical challenges regarding dose planning and attenuation correction of MRI hardware and immobilization devices by generating Pseudo-CT, using methods based on ultra-short echo time (UTE) MR sequence. Additionally, investigators desire to assess how the complementary information provided by multi-parametric PET/MRI can affect the planning of EBRT and BT and contribute to better understanding of the pathology of cervical cancer during chemo-radiotherapy and improve radiation treatment.

The PET/MR will be performed with a new PET-tracer "RGD" (68Ga-NODAGA- E[c(RGDyK)]2) enabling imaging of tumor-angiogenesis. This is to show the angiogenesis within the tumor and changes during external radiotherapy. The study of angiogenesis will be supported by examination of tissues from the tumor.

Investigators expect the angiogenesis to correlate to the aggression and thereby the prognosis of the individual tumor.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 25
• Est. completion date: September 1, 2021
• Est. primary completion date: September 1, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed with cervical cancer stage

• Tumor > 1cm

• Referred for EBRT and BT planning

• Age > 18 years

• Informed consent

Exclusion Criteria:

• Prior RT of the pelvic region

• Pregnancy and lactation

• Claustrophobia

• MR-incompatible implants

Related Conditions & MeSH terms

• Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Drug:
• 68Ga-NODAGA-E[c(RGDyK)]2
200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 will be administered before external beam radiation therapy (EBRT).

Device:
• PET/MRI scan instead of only MRI
Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning external beam radiation therapy.

Drug:
• 68Ga-NODAGA-E[c(RGDyK)]2
200 MBq 68Ga-NODAGA-E[c(RGDyK)]2 will be administered before brachytherapy (BT).

Device:
• PET/MRI scan instead of only MRI
Following injection of RGD-PET the patients will be subjected to PET/MRI of the pelvic for planning brachytherapy.

Locations

Country	Name	City	State
Denmark	University Copenhagen	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of PET/MRI in radiation treatment planning workflow	Assess the feasibility of PET/MRI in the radiation treatment planning workflow with respect to the adequacy of tumor delineation and planning target volume using PET/MRI data as compared to MRI-only planning.	1 year
Primary	Measure of angiogenesis with 68Ga-NODAGA-E[c(RGDyK)]2 radio-tracer in patient with cervical cancer	Measure of voxel values, metabolic volume represents angiogenesis volume in patients with cervical cancer. Angiogenesis can be analysed qualitatively.	1 hour
Secondary	Feasibility of dose planning using MRI	evaluate the feasibility of performing dose planning based on MRI-only obtained from a PET/MRI system by applying new sequence.	1 year
Secondary	Changes in PTV between conventional MRI and PET/MRI	Compare changes in planning target volume (PTV) and tumor delineation between conventional MRI and PET/ MRI planning.	1 month
Secondary	measuring tumor metabolism using Standard Uptake Value (SUV).	Tumor metabolism in cancer cells prior to external beam radiation therapy as well as brachytherapy can be measured by SUV which depends on patient weight and injected activity.	1 hour